Centessa Pharmaceuticals plc ADR [CNTA] stock is trading at $14.03, up 3.47%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CNTA shares have gain 6.53% over the last week, with a monthly amount glided 17.70%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] stock has seen the most recent analyst activity on May 28, 2025, when Needham initiated its Buy rating and assigned the stock a price target of $35. Previously, Chardan Capital Markets started tracking the stock with Buy rating on May 08, 2025, and set its price target to $30. On March 31, 2025, Piper Sandler initiated with a Overweight rating and assigned a price target of $38 on the stock. TD Cowen started tracking the stock assigning a Buy rating. Morgan Stanley upgraded its rating to a Overweight and raised its price target to $26 on September 20, 2024. B. Riley Securities started tracking with a Buy rating for this stock on September 19, 2024, and assigned it a price target of $33. In a note dated July 18, 2024, Oppenheimer initiated an Outperform rating and provided a target price of $14 on this stock.
Centessa Pharmaceuticals plc ADR [CNTA] stock has fluctuated between $9.00 and $19.09 over the past year. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $14.03 at the most recent close of the market. An investor can expect a potential return of 49.68% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -13.05%, Pretax Profit Margin comes in at -14.7%, and Net Profit Margin reading is -14.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.57 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.56 points at the first support level, and at 13.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.60, and for the 2nd resistance point, it is at 15.18.
Ratios To Look Out For
For context, Centessa Pharmaceuticals plc ADR’s Current Ratio is 14.37. Also, the Quick Ratio is 14.37, while the Cash Ratio stands at 4.34. Considering the valuation of this stock, the price to sales ratio is 124.43, the price to book ratio is 4.85.
Transactions by insiders
Recent insider trading involved Weinhoff Gregory M, Chief Business Officer, that happened on Jun 25 ’25 when 10000.0 shares were sold. General Counsel, HUSSAIN IQBAL J completed a deal on Jun 24 ’25 to sell 12000.0 shares. Meanwhile, President, Orexin Program Accardi Mario Alberto sold 15000.0 shares on Jun 24 ’25.
